Swedbank AB Boosts Stake in Henry Schein, Inc. $HSIC

Swedbank AB lifted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,312,312 shares of the company’s stock after acquiring an additional 12,741 shares during the period. Swedbank AB owned approximately 1.11% of Henry Schein worth $99,185,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC purchased a new stake in Henry Schein during the second quarter valued at about $25,000. MUFG Securities EMEA plc purchased a new position in shares of Henry Schein in the 2nd quarter worth about $27,000. Flagship Harbor Advisors LLC bought a new position in shares of Henry Schein during the 4th quarter valued at about $30,000. Steph & Co. bought a new position in shares of Henry Schein during the 4th quarter valued at about $52,000. Finally, Tema Etfs LLC purchased a new position in shares of Henry Schein during the 4th quarter valued at about $56,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Henry Schein

In other news, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the sale, the director owned 15,420 shares of the company’s stock, valued at approximately $1,217,563.20. The trade was a 15.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mark E. Mlotek sold 5,925 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total transaction of $478,740.00. Following the transaction, the executive vice president owned 80,554 shares in the company, valued at $6,508,763.20. This represents a 6.85% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 105,911 shares of company stock worth $8,574,982. 0.89% of the stock is owned by corporate insiders.

More Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q1 results beat expectations: HSIC reported $1.32 EPS on $3.37B revenue, topping consensus and showing 6.3% revenue growth and margin improvement — a core reason investors bought the stock after the print. Henry Schein Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dental strength and margin expansion were highlighted by management and reporters, supporting the beat and the company’s message of market?share gains. Reuters: Henry Schein reaffirms annual profit forecast, beats Q1 estimates
• Positive Sentiment: Analyst commentary and screens emphasize HSIC’s value characteristics (attractive P/E, stable cash flows), with Zacks flagging the stock as a strong value pick for some investors. Here’s Why Henry Schein (HSIC) is a Strong Value Stock
• Neutral Sentiment: Company reaffirmed FY?2026 EPS guidance (5.230–5.370) and revenue range roughly in line with consensus — guidance was maintained, not raised, so this is reassuring but not a catalyst. Press release / guidance
• Neutral Sentiment: Earnings call transcript and slide deck are available for deeper detail on segment trends and margin drivers — useful for investors doing diligence. Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Several roundup pieces note mixed analyst views on HSIC — debate centers on execution of margin improvement and growth sustainability rather than any single, clear directional factor. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: At least one shop cut its price target (Mizuho lowered PT from $88 to $82 and set a neutral rating), which can pressure the stock via reduced analyst upside and sentiment. Tickerreport: Mizuho price target cut
• Negative Sentiment: Despite the beat, the stock is trading lower with above?average volume (investors appear to be selling into the print, possibly locking in gains or reacting to the mixed analyst tone). MarketWatch: stock underperforms peers

Henry Schein Trading Down 2.6%

NASDAQ HSIC opened at $72.44 on Thursday. The stock has a market cap of $8.31 billion, a P/E ratio of 21.89, a price-to-earnings-growth ratio of 2.20 and a beta of 0.82. Henry Schein, Inc. has a fifty-two week low of $61.94 and a fifty-two week high of $89.29. The stock has a 50 day simple moving average of $76.32 and a two-hundred day simple moving average of $75.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.36.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.12. The firm had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The business’s revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts forecast that Henry Schein, Inc. will post 5.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HSIC has been the subject of several research reports. Robert W. Baird set a $97.00 target price on Henry Schein in a research note on Wednesday. JPMorgan Chase & Co. lifted their price target on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. UBS Group restated a “neutral” rating and issued a $85.00 price objective (down from $87.00) on shares of Henry Schein in a report on Wednesday. BTIG Research assumed coverage on shares of Henry Schein in a research note on Thursday, April 16th. They issued a “neutral” rating for the company. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $86.83.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.